Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies.

被引：17

作者：

Schram, Alison M.

Ahnert, Jordi Rodon

Patel, Manish R.

Jauhari, Shekeab

Sachdev, Jasgit C.

Zhu, Viola Weijia

LoRusso, Patricia

Nguyen, Danny

Le, Xiuning

O'Connor, Matthew

Waters, Nigel

Cook, Carl

Witt, Karsten

Humphrey, Rachel W.

Janne, Pasi A.

Hamilton, Erika P.

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

[4] Florida Canc Specialists, Sarah Cannon Res Inst, Lake Mary, FL USA

[5] HonorHlth Res Inst, Scottsdale, AZ USA

[6] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA

[7] Yale Univ, Sch Med, New Haven, CT USA

[8] Pacific Shores Med Grp, Long Beach, CA USA

[9] Black Diamond Therapeut Inc, New York, NY USA

[10] Black Diamond Therapeut Inc, Cambridge, MA USA

[11] Dana Farber Canc Inst, Boston, MA 02115 USA

[12] Tennessee Oncol LLC, Sarah Cannon Res Inst, Nashville, TN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.3086

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3086

引用

页数：2

共 32 条

[1] A phase 1 study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD), and to determine the recommended phase 2 dose (RP2D) of subcutaneous (SC) cetrelimab (CET) in patients (pts) with advanced solid malignancies.
Rutkowski, Piotr
Kowalski, Dariusz
Moreno, Victor
Calvo, Aitana
Thistlethwaite, Fiona
Plummer, Elizabeth Ruth
Han, Kevin Tianxiang
Loffredo, John
Carcione, Jenna
Jonathan, Daniel
Philip, Vinod
Baig, Mahadi
Hellemans, Peter
Bulat, Iurie
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Debio 0123+carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)
Gelderblom, H.
Gadea, O. Saavedra Santa
Jalving, M.
Desar, I.
Gietema, J. A.
Oberoi, A.
Van Herpen, C.
Kroep, J. R.
Franzen, R. Frederiksen
Bellon, A.
Micallef, S.
Tat, T.
Dozio, V.
Luong, N.
Imedio, E. Rodrigo
ANNALS OF ONCOLOGY, 2024, 35 : S502 - S503
[3] A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies.
Salgia, Ravi
Hong, David
Sherman, Steven I.
Ng, Chann
Frye, John
Janish, Linda
Ratain, Mark
Kurzrock, Razelle
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3385S - 3385S
[4] A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies
Ribrag, Vincent
Iglesias, Lara
De Braud, Filippo
Ma, Brigette
Yokota, Tomoya
Zander, Thomas
Spreafico, Anna
Subbiah, Vivek
Illert, Anna L.
Tan, Daniel
Santoro, Armando
Munster, Pamela N.
Suehiro, Youko
Wang, Yongsheng
Ji, Dong-Mei
Chen, Shuqi
Beltz, Karen
Suenaga, Naoko
Ramkumar, Thiruvamoor
Luo, Fangjun
Lai, Clinton
Wainberg, Zev A.
EUROPEAN JOURNAL OF CANCER, 2025, 216
[5] First-in-human, phase I, dose-escalation study of selective PI3Kα isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.
Juric, Dejan
De Bono, Johann Sebastian
LoRusso, Patricia
Nemunaitis, John J.
Heath, Elisabeth I.
Kwak, Eunice Lee
Macarulla, Teresa
Geuna, Elena
Luken, Maria Jose de Miguel
Patel, Chirag
Kuida, Keisuke
Sankoh, Serap
Zohren, Fabian
Shou, Yaping
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[6] Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results
Voskoboynik, M.
Mileshkin, L.
Gan, H.
Millward, M.
Au-Yeung, G.
Meniawy, T. M.
Kichenadasse, G.
Zhang, K.
Zhang, M.
Mu, S.
Lickliter, J. D.
ANNALS OF ONCOLOGY, 2019, 30
[7] A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D)
El-Khoueiry, A.
Gitlitz, B.
Cole, S.
Tsao-Wei, D.
Goldkorn, A.
Quinn, D.
Lenz, H. J.
Nieva, J.
Dorff, T.
Oswald, M.
Berg, J.
Menendez, X.
Karakozian, K.
Krasnoperov, V.
Liu, R.
Thomas, J.
Groshen, S.
Gill, P.
EUROPEAN JOURNAL OF CANCER, 2016, 69 : S11 - S11
[8] Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors
Wahlroos, Sara
Teng, Christina
Tran, Ben
Voskoboynik, Mark
Gan, Hui Kong
Spencer, Andrew
Kudva, Anupa
Song, Ming
Lynch, Kevin
Yu, Zhinuan
Desai, Jayesh
Lemech, Charlotte Rose
Lifehouse, Chris O'Brien
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] A phase I, dose-escalation, multicenter study of ACT-PFK-158, 2HCl in patients with advanced solid malignancies explores a first-in-human inhibitor of glycolysis
Redman, Rebecca Ann
Pohlmann, Paula Raffin
Kurman, Michael R.
Tapolsky, Gilles
Chesney, Jason
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[10] Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and antitumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)
Olszanski, A. J.
Luke, J. J.
LoRusso, P. M.
Falchook, G. S.
Bedard, P. L.
Sanborn, R. E.
Patel, S. P.
Orr, D.
Gibbs, J. P.
Li, C.
Huang, Y-C.
Gregory, R.
Perera, S.
Xu, R.
Joshi, A.
Lee, M. Y.
Raizer, J.
Gao, X.
ANNALS OF ONCOLOGY, 2023, 34 : S625 - S626

← 1 2 3 4 →